Stock Taper 
ALVOW
$0.30
▼ DOWN 6.25% (-0.02)
KEY STATISTICS
Market Cap$2.79 B
52w High$1.52
52w Low$0.30
Dividend Yield—
Frequency—
P/E43.73
Volume100
Shares Out.312.90M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Lisa Graver
ABOUT
SECTOR
Healthcare
WENT PUBLIC
June 16, 2022
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
1,460
UPCOMING EARNINGS
DateNov 11, 2026
DayWednesday
Rev. Est.$136.78M
NOV
11
WED
PRICE
$0.30 ▼ DOWN 6.25% (−$0.02)About Alvotech
https://www.alvotech.com ↗Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland.
INDUSTRY
Drug Manufacturers - Specialty & Generic
A PRODUCT ALVOTECH IS KNOWN FOR
Gobivaz (AVT05)
Gobivaz, Alvotech's first globally marketed biosimilar to Simponi® (golimumab), was launched in Europe in December 2025 to treat immune-mediated inflammatory diseases.
Revenue by Products
| Icon | PRODUCT | FY2023 |
|---|---|---|
 | Humira | $12.2B |
Revenue by Geography
| Map | REGION | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
 | Europe | $39.43M | $63.51M ▲ | $157.59M ▲ | $307.22M ▲ |
 | UNITED STATES | — | — | $273.04M | $241.37M ▼ |
 | Rest of the World | — | — | $59.06M | $37.73M ▼ |
 | North America | $30.78M | $18.31M ▼ | — | — |
 | Asia And Other | — | $9.62M | — | — |
 | Asia | $6.8M | — | — | — |
 | Other Geographical Area | $6.02M | — | — | — |
ETFS HOLDING THIS STOCK
ETFS HOLDING
30
LISTED HERE
1
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
1.77%
HOLDERS
15
TOP 12 OF 15 · RANKED BY POSITION SIZE
Oaktree Capital Management LP
Serengeti Asset Management LP
Linden Advisors LP
Arena Capital Advisors, LLC- Ca
Jane Street Group, LLC
Moore Capital Management, LP
Wolverine Asset Management LLC
Bluefin Capital Management, LLC
Sculptor Capital LP
Highbridge Capital Management LLC
Clear Street LLC
Clear Street Group Inc.
INDV
SUPN
BHC
PRGO